Otlertuzumab (TRU-016)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 14:29, 11 December 2014 by Jwarner (talk | contribs) (Created page with "==Mechanism of action== Anti-CD37 antibody. CD37 is a cell surface tetraspanin. ==Preliminary data== # Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP, Spurg...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Mechanism of action

Anti-CD37 antibody. CD37 is a cell surface tetraspanin.

Preliminary data

  1. Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP, Spurgeon SE, Andritsos LA, Gopal AK, Leonard JP, Eisenfeld AJ, Bannink JE, Stromatt SC, Furman RR. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood. 2014 Feb 27;123(9):1302-8. Epub 2013 Dec 31. PubMed
  2. Gopal AK, Tarantolo SR, Bellam N, Green DJ, Griffin M, Feldman T, Mato AR, Eisenfeld AJ, Stromatt SC, Goy A. Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Invest New Drugs. 2014 Dec;32(6):1213-25. Epub 2014 Jun 15. PubMed
  3. Pagel JM, Spurgeon SE, Byrd JC, Awan FT, Flinn IW, Lanasa MC, Eisenfeld AJ, Stromatt SC, Gopal AK. Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients. Br J Haematol. 2015 Jan;168(1):38-45. Epub 2014 Aug 22. [PubMed http://www.ncbi.nlm.nih.gov/pubmed/25146490]
Retrieved from "https://hemonc.org/w/index.php?title=Otlertuzumab_(TRU-016)&oldid=6289"